Andreas Du Bois
#164,554
Most Influential Person Now
Researcher
Andreas Du Bois's AcademicInfluence.com Rankings
Andreas Du Boisphilosophy Degrees
Philosophy
#9625
World Rank
#13213
Historical Rank
Logic
#6592
World Rank
#8123
Historical Rank
Download Badge
Philosophy
Why Is Andreas Du Bois Influential?
(Suggest an Edit or Addition)Andreas Du Bois's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) (1582)
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) (1534)
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials (2009) (1269)
- A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. (2003) (1031)
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) (838)
- Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. (2009) (532)
- Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. (2006) (530)
- Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. (2010) (513)
- Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. (2010) (509)
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) (2010) (495)
- Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. (2011) (472)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. (2003) (466)
- 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). (2005) (425)
- Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. (2005) (391)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019) (385)
- GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013) (350)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer. (2014) (304)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (2019) (287)
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. (2012) (242)
- Breast cancer in pregnancy: recommendations of an international consensus meeting. (2010) (236)
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer (2010) (234)
- Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO (2010) (232)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2019) (207)
- Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. (2009) (205)
- Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. (2009) (200)
- Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. (2006) (199)
- Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. (2013) (196)
- Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). (2007) (190)
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. (2016) (190)
- Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. (2010) (189)
- Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau (2006) (188)
- Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. (2010) (186)
- Advanced epithelial ovarian cancer: 1998 consensus statements. (1999) (180)
- ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. (2014) (177)
- Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. (2011) (176)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease (2017) (172)
- Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study (2015) (169)
- Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
- Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. (2004) (163)
- Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. (2010) (157)
- Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. (2008) (144)
- Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer (2006) (138)
- Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. (2016) (136)
- Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer (2004) (131)
- Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis (2009) (130)
- Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. (2006) (129)
- Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. (2015) (128)
- Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? (2013) (127)
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (2018) (115)
- Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy (2009) (111)
- Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting (2009) (111)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 (2013) (110)
- Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. (2010) (109)
- Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. (2009) (105)
- Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium (2015) (104)
- Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort (2011) (101)
- European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery (2016) (96)
- Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. (2013) (94)
- Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) (2017) (93)
- First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? (1999) (92)
- Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer (2004) (88)
- Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). (2007) (88)
- Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. (2006) (86)
- Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. (2006) (85)
- Incidence of bisphosphonate‐associated osteonecrosis of the jaws in breast cancer patients (2009) (85)
- Intraperitoneal chemotherapy in ovarian cancer remains experimental. (2006) (85)
- Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes (2017) (83)
- Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. (2011) (83)
- Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). (2004) (82)
- Genome-wide significant risk associations for mucinous ovarian carcinoma (2015) (81)
- Treatment of recurrent ovarian cancer. (2017) (81)
- A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection (2011) (79)
- Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. (2020) (75)
- HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer (2015) (73)
- Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. (1992) (72)
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. (2012) (72)
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. (2021) (72)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors) (2014) (71)
- First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. (2010) (70)
- NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. (2008) (69)
- Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. (2013) (67)
- Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. (2010) (67)
- TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7) (2019) (66)
- The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. (2006) (66)
- Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. (2004) (65)
- Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. (1997) (64)
- Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. (2001) (63)
- Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2018) (63)
- The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence (2005) (62)
- Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial. (2004) (61)
- Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review (2019) (60)
- FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. (2016) (60)
- Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. (2004) (60)
- Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity (1998) (58)
- Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. (2005) (58)
- Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration (2018) (58)
- Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. (2016) (58)
- Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. (2006) (58)
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. (2010) (58)
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. (2013) (57)
- The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. (2017) (57)
- Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). (2007) (57)
- Mediation analysis of the relationship between institutional research activity and patient survival (2014) (56)
- Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A (2009) (55)
- Incidence Patterns and Temporal Trends of Invasive Nonmelanotic Vulvar Tumors in Germany 1999-2011. A Population-Based Cancer Registry Analysis (2015) (55)
- Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (2011) (53)
- Ovarian carcinoma diagnosis: the clinical impact of 15 years of change (2016) (53)
- Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). (2006) (52)
- Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer (2015) (50)
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). (2016) (50)
- Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (2007) (49)
- Future options for first‐line therapy of advanced ovarian cancer (2005) (49)
- Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs (2010) (48)
- Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study (2014) (47)
- SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT OVARIAN CANCER (2003) (46)
- BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. (2016) (46)
- Carboplatin Hypersensitivity: Does Introduction of Skin Test and Desensitization Reliably Predict and Avoid the Problem? A Prospective Single-Center Study (2009) (46)
- Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. (2014) (46)
- Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. (2014) (45)
- Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. (2005) (44)
- Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. (2014) (44)
- Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. (2011) (44)
- Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. (2019) (44)
- Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. (2016) (43)
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. (2011) (43)
- First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. (1999) (42)
- Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. (2005) (42)
- The role of surgery in recurrent ovarian cancer (2005) (42)
- Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. (2014) (42)
- Management of borderline ovarian tumors. (2016) (41)
- Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. (2016) (41)
- Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update (2020) (41)
- Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. (1997) (40)
- Abdominal Wall Metastases in Patients With Ovarian Cancer After Laparoscopic Surgery: Incidence, Risk Factors, and Complications (2009) (40)
- Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. (2013) (39)
- Treatment of recurrent ovarian cancer. (2017) (39)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (39)
- HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? (2018) (38)
- Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study (2017) (38)
- S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. (2013) (38)
- Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk (2015) (36)
- Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy (1999) (36)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Small Cell Cancers (2014) (36)
- Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) (2019) (36)
- Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. (2017) (36)
- The Systemic Treatment of Recurrent Ovarian Cancer revisited. (2021) (35)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2015) (35)
- Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al (2017) (35)
- Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study (2015) (35)
- A new standard of care for treatment of ovarian cancer. (2000) (34)
- Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial (2018) (34)
- Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy (2010) (34)
- Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. (1997) (34)
- Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer (2016) (34)
- Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. (2014) (34)
- Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. (2004) (34)
- Therapeutic strategies in cervical pregnancy. (1994) (33)
- Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer (2009) (33)
- Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial (2013) (33)
- A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. (2012) (32)
- VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection (2009) (32)
- Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). (2007) (32)
- Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium (2015) (31)
- Clinical management of borderline ovarian tumors (2010) (31)
- Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. (2010) (31)
- European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies (2010) (31)
- Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study (2015) (30)
- Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity (2004) (30)
- Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer (2019) (29)
- Clinical research in epithelial ovarian cancer and patients' outcome. (2011) (29)
- When should Surgery be used for Recurrent Ovarian Carcinoma? (2018) (29)
- Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance (2013) (29)
- ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors (2021) (29)
- Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. (2012) (29)
- Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma (2020) (28)
- Specialized Pathology Review in Patients With Ovarian Cancer: Results From a Prospective Study (2013) (27)
- Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. (2012) (27)
- Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. (2006) (27)
- Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. (1996) (27)
- Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. (1997) (27)
- Current and future options in the management and treatment of uterine sarcoma (2014) (27)
- Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. (1997) (26)
- Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. (2019) (26)
- Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. (2015) (26)
- Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) (2015) (26)
- Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. (2020) (25)
- Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. (1996) (25)
- Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes (2009) (25)
- Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. (2013) (25)
- Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy (2017) (24)
- Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol) (2009) (24)
- Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. (2020) (24)
- A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). (2005) (23)
- Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? (2007) (23)
- Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study (2009) (23)
- ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors (2021) (22)
- Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. (2019) (22)
- German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients (2017) (22)
- Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome (2013) (22)
- Low-grade Serous Ovarian Carcinoma (2018) (22)
- Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group (2012) (22)
- Borderline Tumors of the Ovary: Clinical Course and Prognostic Factors (2012) (22)
- The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified? (2016) (21)
- Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk (2015) (21)
- c‐jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines (1995) (21)
- The changing landscape of therapeutic strategies for recurrent ovarian cancer. (2012) (21)
- Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study. (2013) (20)
- Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. (2014) (20)
- Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer. (2013) (20)
- Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. (2020) (20)
- Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition (2015) (20)
- Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (2009) (20)
- Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome (2014) (20)
- Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries (2018) (20)
- Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. (2017) (20)
- Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin. (1998) (19)
- Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study (2019) (19)
- A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). (2005) (19)
- The role of surgery in advanced and recurrent ovarian cancer. (2006) (19)
- Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer (2016) (19)
- Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience (2012) (19)
- A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: An evidence-based proposal for patient selection. (2011) (19)
- Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? (2020) (18)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Recurrent cytogenetic aberrations and loss of constitutional heterozygosity in ovarian carcinomas. (1994) (18)
- A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. (1997) (18)
- Combining conventional therapy with immunotherapy: A risky business? (2019) (18)
- Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. (2020) (18)
- [The Arabin cerclage pessary--an alternative to surgical cerclage]. (1990) (18)
- Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases (2016) (17)
- Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer (2015) (17)
- Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. (1996) (17)
- Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. (2015) (17)
- [Impact of center characteristics on outcome in ovarian cancer in Germany]. (2005) (17)
- Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (2016) (16)
- Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. (2016) (16)
- Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. (2010) (16)
- Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva (2009) (16)
- Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. (2013) (16)
- The integration of anthracyclines in the treatment of advanced ovarian cancer (2001) (16)
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015 (2015) (16)
- Fertility-Sparing Surgery in Ovarian Cancer: A Systematic Review (2013) (16)
- Abagovomab for ovarian cancer (2011) (15)
- Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. (1997) (15)
- Para‐aortic lymph node metastasis in malignant dysgerminoma of the ovary (2009) (15)
- Compliance to Consensus Recommendations, Surgeon's Experience, and Introduction of a Quality Assurance and Management Program: Influence on Therapy of Early-Stage Ovarian Carcinoma (2009) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- Anthracycline and trastuzumab in breast cancer treatment. (2004) (15)
- Role of cytoreductive surgery in recurrent ovarian cancer (2009) (14)
- Tracheal Tube Obstruction in Mechanically Ventilated Patients Assessed by High-resolution Computed Tomography (2014) (14)
- [Value of high resolution sonography in breast cancer screening]. (2008) (14)
- Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. (1999) (13)
- Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. (2020) (13)
- What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer. (2009) (12)
- Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial (2019) (12)
- Oxaliplatin in ovarian cancer. (1999) (12)
- A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. (2012) (12)
- Neoadjuvant chemotherapy in ovarian cancer revisited. (2016) (12)
- Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients. (2015) (12)
- Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. (1994) (12)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (12)
- The Sandwich Technique of Diaphragmatic Stripping or Full-Thickness Resection for Advanced Ovarian Cancer: How to Keep it Short and Simple (2015) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer. (1997) (11)
- Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. (2014) (11)
- Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. (2011) (10)
- Pattern of carboplatin‐induced emesis (1995) (10)
- Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial. (1997) (10)
- Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging (2020) (10)
- TOPOTECAN VERSUS TREOSULFAN IN EARLY RECURRENT OVARIAN CANCER AFTER PRIMARY PLATINUM/ PACLITAXEL CHEMOTHERAPY. A PROSPECTIVE RANDOMIZED PHASE III TRIAL OF THE AGO OVARIAN CANCER STUDY GROUP (2004) (10)
- Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer (2014) (10)
- Ovarian cancer—can intraperitoneal therapy be regarded as new standard in Germany? (2006) (10)
- Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. (1995) (10)
- The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study (2015) (10)
- Expression of transcripts for CSF-1 and for the "macrophage" and "epithelial" isoforms of the CSF-1R transcripts in human ovarian carcinomas. (1994) (10)
- Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7) (2016) (9)
- Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC) (2021) (9)
- Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions (1997) (9)
- Operative and Conservative Treatment of Uterine Sarcomas. (2014) (9)
- Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility (2018) (9)
- State-of-the-Art First-Line Treatment of Ovarian Cancer (2003) (9)
- Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV) (2020) (9)
- Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patients (2020) (9)
- 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. (2005) (9)
- A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers. (2006) (9)
- Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany (2009) (9)
- Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer (2019) (9)
- Improving first‐line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective (2003) (9)
- The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens (1997) (8)
- Is there a role for HIPEC in ovarian cancer? (2018) (8)
- Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials (2013) (8)
- Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. (2019) (8)
- Accelerating type‐specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high‐throughput tool for case review (2013) (8)
- A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours (2005) (8)
- Patient-reported outcomes in ovarian cancer: are they key factors for decision making? (2018) (8)
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. (2012) (8)
- Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer. (2012) (8)
- Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. (2017) (7)
- Dilution of Molecular–Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer (2019) (7)
- Impact of Treatment Guidelines and Implementation of a Quality Assurance Program on Quality of Care in Endometrial Cancer (2009) (7)
- [Leiomyomatosis peritonealis disseminata and borderline lesion]. (2005) (7)
- 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. (1996) (7)
- [Disseminated, highly malignant non-Hodgkin's lymphoma and pregnancy: polychemotherapy in the 2d and 3d trimester]. (1990) (7)
- ESGO statement on cervical cancer vaccination: August 2007 (2007) (7)
- Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). (2006) (7)
- DNA flow cytometry in stage IB and II cervical carcinoma (1995) (7)
- [Histological grading of epithelial ovarian cancer. Review and recommendation]. (2014) (7)
- ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours (2021) (7)
- Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial. (2004) (7)
- The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer (2011) (7)
- [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]. (2001) (7)
- [The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001]. (2005) (7)
- History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. (2005) (6)
- Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC (2005) (6)
- [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. (2000) (6)
- [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities]. (1997) (6)
- Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series (2019) (6)
- Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment. (2010) (6)
- [First-line therapy in ovarian cancer]. (2004) (6)
- Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914]. (2016) (6)
- Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery. (2019) (6)
- [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]. (2006) (6)
- Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations (2020) (6)
- Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer (2010) (6)
- Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles (2019) (6)
- Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin (2016) (5)
- Future options for first-line therapy of advanced ovarian cancer (2005) (5)
- A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients. (2009) (5)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial (2016) (5)
- [Effect of pregnancy on the incidence and course of malignant diseases]. (1993) (5)
- Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients (2021) (5)
- Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer. (1997) (5)
- Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas (2021) (5)
- Surgery for Recurrent Ovarian Cancer (2011) (5)
- LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial (2020) (5)
- Outcome of Early Breast Cancer Treated in an Urban and a Rural Breast Cancer Unit in Germany (2013) (5)
- Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery? (2011) (5)
- European Surgical Education and Training in Gynecologic Oncology: The impact of an Accredited Fellowship (2017) (5)
- Surgical intervention in relapsed ovarian cancer is beneficial: pro. (2013) (5)
- Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation? (2020) (5)
- Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet (2020) (5)
- [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies]. (2014) (4)
- rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) (4)
- The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. (2015) (4)
- First-Line Chemotherapy in Advanced Ovarian Cancer: State of the Art and Future Aspects (1999) (4)
- MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021) (4)
- Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial (2021) (4)
- Combined radio-chemotherapy in advanced cervical cancer: a phase-II trial with weekly applied carboplatin, 5-fluorouracil and folinic acid (1995) (4)
- Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first‐line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO‐GINECO GCIG Intergroup phase III trial (2005) (4)
- Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. (2019) (4)
- A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients. (2009) (4)
- [Changes in serotonin metabolism in pre-eclampsia]. (1996) (4)
- Combination therapy with pegylated liposomal doxorubicin and carboplatin in malignant gynecologic tumors. A prospective multicenter phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut). (2006) (4)
- Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey (2020) (4)
- Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity (2012) (4)
- Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression". (2017) (4)
- Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group (2020) (4)
- Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring (2021) (4)
- Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. (2017) (4)
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial (2023) (4)
- Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients (2018) (3)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. (2017) (3)
- Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. (1995) (3)
- Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors (2020) (3)
- No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2016) (3)
- Introduction to the Pre–International Gynecologic Cancer Society Roundtable Meeting: successful management of ovarian cancer (2005) (3)
- [Effect of pregnancy and labor on serotonin metabolism]. (1995) (3)
- Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial (2019) (3)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) (3)
- [Central pathology review. Inclusion criterion for clinical studies of ovarian carcinomas?]. (2008) (3)
- Mitomycin C in Combination with Vinorelbine in Anthracycline- and/or Taxane-Pretreated Patients with Metastatic Breast Cancer (2012) (3)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. (2011) (3)
- Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib. (2015) (3)
- Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling. (2022) (3)
- [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum]. (2000) (3)
- [Therapeutic standards for ovarian cancer]. (2007) (3)
- The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group (2021) (3)
- Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data. (2021) (3)
- Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome (2022) (2)
- Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma. (2020) (2)
- Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3+LN): Eight-year follow-up analysis. (2011) (2)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. (2016) (2)
- Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma (2021) (2)
- Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. (2022) (2)
- Prognostic impact of the time interval between primary surgery and start of first-line chemotherapy in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials. (2009) (2)
- [Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results]. (2007) (2)
- Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer (2018) (2)
- NEUROPROTECTION WITH AMIFOSTINE IN THE 1ST-LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH CARBOPLATIN/TAXANE-BASED CHEMOTHERAPY – A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP (2004) (2)
- 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT (2021) (2)
- Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer (2021) (2)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) (2)
- Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review (2016) (2)
- Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC (2005) (2)
- Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy - a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). (2004) (2)
- Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. (2015) (1)
- The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership (2015) (1)
- [Sequential course and prospective management of ifosfamide-induced multi-organ toxicity]. (1996) (1)
- 241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators (2021) (1)
- Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database (2022) (1)
- Anti-idiotypic antibody abagovomab in advanced ovarian cancer. (2008) (1)
- Homologous recombination deficiency testing in first-line ovarian cancer. (2022) (1)
- Feasibility of internal inguinoperitoneal drainage after inguinofemoral lymphadenectomy in vulvar cancer (2020) (1)
- Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience (2021) (1)
- MONITOR VII: Treatment strategies of low grade ovarian carcinomas - A German survey of the Charité - Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO. (2018) (1)
- Treatment of advanced ovarian cancer. (2001) (1)
- Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer (2022) (1)
- Significant Overall Survival Improvement In Proliferative Subtype Ovarian Cancer Patients Receiving Bevacizumab (2018) (1)
- [Doppler ultrasound in high grade multiple pregnancies]. (1993) (1)
- 181PVALIDATION OF MODELED EARLY LONGITUDINAL CA-125 KINETICS FOR PREDICTING SURVIVAL IN OVARIAN CANCER (OC) PHASE III TRIALS: COULD THE FAILURE OF ADDING GEMCITABINE TO CARBOPLATIN-PACLITAXEL (AGO-OVAR 9) HAVE BEEN FORESEEN EARLIER IN THE TRIAL? (2014) (1)
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (2018) (1)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (1)
- Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: A combined explorative analysis of three prospective phase III trials from the AGO study group. (2011) (1)
- 880PDPAZOPANIB VERSUS PLACEBO IN WOMEN WITHOUT PROGRESSION AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (AEOC): SECOND INTERIM OVERALL SURVIVAL ANALYSIS FROM THE AGO-OVAR16 TRIAL. (2014) (1)
- Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era (2022) (1)
- Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study (2016) (1)
- [Effectiveness and cost of 5-HT3-antagonists in acute chemotherapy-induced emesis. Health-economic analysis based on current meta-analytic data]. (1997) (1)
- The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. (2011) (1)
- 0755: Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (Gcig) (2006) (1)
- Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery” (2016) (1)
- Cytoreductive Surgery for Relapsed Ovarian Cancer. Reply. (2022) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial (2022) (1)
- 291 Frequency of pathogenic mutations and prognostic impact of germline gene panel testing in patients with primary epithelial ovarian cancer (2021) (1)
- EPIRUBICIN/PACLITAXEL/CARBOPLATIN (TEC) VERSUS PACLITAXEL/CARBOPLATIN (TC) IN FIRST-LINE TREATMENT OF OVARIAN CANCER FIGO STAGES IIB-IV. MATURE RESULTS OF A RANDOMIZED AGO-GINECO GCIG INTERGROUP PHASE III TRIAL (2004) (1)
- [Management of Werlhof disease in pregnancy complicated by diabetes mellitus type I]. (1999) (0)
- Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study. (2011) (0)
- Incidence of recurrence and prognostic factors of borderline tumors of the ovary. (2011) (0)
- [Fetomaternal transfusion in relation to mode of delivery. Comparison of data from the DFG multicenter study "Rhesus negative" (1965-70) with data from the Freiburg University Gynecologic Clinic (1989)]. (1991) (0)
- [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. (1998) (0)
- 533P Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group) (2022) (0)
- Making the most of every option in the treatment of ovarian cancer (2016) (0)
- 000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) (2005) (0)
- Rare gynecological cancers in a gynecologic cancer center: 11-year experience of KEM (2022) (0)
- P133 Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery (2019) (0)
- 560 Analysis of 168 primary adult ovarian granulosa cell tumors, its clinicopathological outcome, and risk factors for recurrence (2021) (0)
- Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group). (2022) (0)
- Chemotherapy Response Score: Correlation with preoperative assessment of serological response and clinical implications in ovarian cancer patients (2020) (0)
- Long-term survival of early stage I epithelial ovarian cancer: A multicenter retrospective observational study (321) (2022) (0)
- EP1223 Fertility-sparing surgery in patients with borderline ovarian tumors and reproductive outcomes (2019) (0)
- Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant. (2022) (0)
- Incidence and prognostic impact of pathogenic germline mutations in gene panel testing of primary advanced epithelial ovarian cancer patients (2022) (0)
- Some thoughts about surgery in ovarian cancer 2021 (2021) (0)
- 573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial (2022) (0)
- [Transvaginal color-coded Doppler ultrasound in ovarian tumors]. (1994) (0)
- EP869 Treatment of ovarian cancer in Germany from 2004–2016: results of a nationwide quality assurance program (QS Ovar) (2019) (0)
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. (2022) (0)
- Prospective identification of prognostic factors for patients with early failure of advanced ovarian cancer who undergo primary cytoreductive surgery followed by chemotherapy: The AGO-OVAR 19/FRAGILE study (NCT02828618). (2022) (0)
- „Low Anterior Resection Syndrome“ (LARS) bei Patientinnen mit epithelialem Ovarialkarzinom. (2019) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- 0074: Combination Therapy with Pegliposomal Doxoru-Bicin and Carboplatin in Gynecologic Tumours. a Phase-Ii Trial of the Ago-Ovar and the Ago Kommission Uterus (2006) (0)
- LION-PAW – Lymphonodectomy (LNE) in Ovarian Neoplasm – Pleasure Ability of Women Prospektive Substudie der multizentrischen AGO LION Studie (2018) (0)
- Surgical lymph node staging in locally advanced cervical carcinoma (2022) (0)
- 00010 ANTIANGIOGENESIS - A NEW TREATMENT MODALITY FOR OVARIAN CANCER PATIENTS (2005) (0)
- 0072: Safety and Pharmacokinetic Aspects of Anti-Angiogenic Therapy with Ptk787/Zk 222584 in Combination with Paclitaxel/Carboplatin in Patients with Ovarian Cancer (2006) (0)
- 0003: Gemcitabine-Paclitaxel-Carboplatin (TCG) VS. Paclitaxel-Carboplatin (TC) in Ovarian Cancer (OC): A Randomized Phase III Gcig Study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102) (2006) (0)
- Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer (2019) (0)
- [Ovarian cancer -- can peritoneal therapy be regarded as new standard?]. (2006) (0)
- Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study (2016) (0)
- GEFINITIB IN COMBINATION WITH TAMOXIFEN IN PATIENTS WITH OVARIAN CANCER REFRACTORY TO PLATINUM-TAXANE BASED THERAPY – A PHASE II STUDY OF THE AGO OVAR (2004) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Lymphadenectomy in Advanced Ovarian Neoplasms. Reply. (2019) (0)
- LOCALIZATION AND PREDICTION OF LYMPH NODE (LN) METASTASES IN OVARIAN CANCER (OC) (2004) (0)
- Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (2011) (0)
- [Fetomaternal transfusions in complicated and uncomplicated pregnancy]. (1991) (0)
- [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F]. (1990) (0)
- Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study (2022) (0)
- Role of substage and histologic subtype in stage I epithelial ovarian cancer survival: a multicenter retrospective observational study (2022) (0)
- Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial (2022) (0)
- Therapy of ovarian cancer (OC) in Germany – Treatment characteristics and survival results of the QS OVAR 2012 (2018) (0)
- Mammographic screening: no reliable supporting evidence? (2002) (0)
- Survival of patients with advanced ovarian cancer in a specialized center from 1998 – 2016 (2018) (0)
- Expectation and perception of chemotherapy side effects differ between breast and ovarian cancer patients, age at diagnosis and the individual need for psycho-oncological support (2018) (0)
- Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective (2003) (0)
- DESCRIPTIVE EVALUATION OF PRE-OPERATIVE SELECTION CRITERIA FOR OPERABILITY IN RECURRENT OVARIAN CANCER (DESKTOP-OVAR). A STUDY OF THE AGO OVARIAN CANCER STUDY GROUP AND THE AGO ORGANKOMMISSION OVAR (2004) (0)
- [The course of pregnancy in patients with malignancies]. (1993) (0)
- 854 Surgical lymph node staging in locally advanced cervical carcinoma (2021) (0)
- The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer (2021) (0)
- The role of factor (f) XIII in patients with advanced epithelial ovarian cancer (EOC) FIGO III/IV (2020) (0)
- 0016: Practice Patterns of Radiotherapy in Cervix Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG) (2006) (0)
- 123 Real world data of treatment and outcome of patients with high grade AOC (advanced ovarian cancer) in Germany (QS Ovar) (2021) (0)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (0)
- 0178: Oral Gimatecan in Women with Progressing or Recurring Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers (2006) (0)
- Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence (2023) (0)
- [What is current status? Current status in the primary therapy of advanced ovarian cancer]. (1999) (0)
- Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II). (2022) (0)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (0)
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. (2018) (0)
- 2022-RA-1008-ESGO The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer (2022) (0)
- 00096 PRE-OPERATIVE SELECTION CRITERIA FOR OPERABILITY IN RECURRENT OVARIAN CANCER (DESKTOP-OVAR) (2005) (0)
- Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation (2022) (0)
- [Advances in the treatment of ovarian carcinoma]. (2004) (0)
- [Fetomaternal transfusions in early pregnancy]. (1991) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- PEGLIPOSOMAL DOXORUBICIN (PLD) AND CARBOPLATIN (C) FOR GYNAECOLOGICAL TUMOURS – PHASE I/II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP (2004) (0)
- Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients (2023) (0)
- Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB–IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial (2005) (0)
- Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al (2021) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system (2019) (0)
- Foreword (2018) (0)
- Therapy of ovarian cancer (OC) in Germany – Treatment characteristics QS OVAR 2016 (2019) (0)
- The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer (2022) (0)
- VEGF-A and COX-2 expression correlate with platinum resistance in ovarian cancers. (2006) (0)
- Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab (2018) (0)
- Low anterior resection syndrome in ovarian cancer patient: a prospective longitudinal study (2022) (0)
- P81 Higher detection rate of lynch syndrome in patients with endometrial cancer by assessment of mismatch repair deficiency (2019) (0)
- Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group (2023) (0)
- 00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER (2005) (0)
- 1056 Live surgical broadcast and patient outcome – 10 years of experience from the international Charité MAYO conferences 2010–2019 (2021) (0)
- [Pharmacotherapy in ovarian carcinoma]. (2005) (0)
- Impact of quantitative body composition on survival in patients with epithelial ovarian cancer undergoing primary debulking surgery (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Andreas Du Bois?
Andreas Du Bois is affiliated with the following schools:
